About
Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis. The companys drug-development process is based on a new platform for anti-necrosis technology. The prevention and treatment of necrosis is significant to the treatment of numerous pathological conditions and diseases. Ela Pharmas technology is based on a novel approach that directly inhibits an intracellular proteolytic enzyme that plays a critical role in the regulation of necrosis pathways. Ela Pharmas first line of anti-necrosis agents is based on small molecules with structural features suitable for inhibiting a specific cellular target, which were found to significantly inhibit cell necrosis at particularly low concentrations.
Funding history · 1 round · $77K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Ela Pharma's primary focus in drug development?
- Ela Pharma is a biotechnology company focused on developing innovative drugs to address clinical conditions caused by necrosis, utilizing a new platform for anti-necrosis technology.
- When was Ela Pharma founded?
- Ela Pharma was founded in June 2015.
- Where is Ela Pharma headquartered?
- Ela Pharma is headquartered in Tel Aviv-Yafo, Israel.
- How many employees does Ela Pharma currently have?
- Ela Pharma currently has 2 employees.
- What is the total amount of funding Ela Pharma has raised?
- Ela Pharma has raised a total of $77,000 USD.
- When did Ela Pharma receive its last funding round and what type was it?
- Ela Pharma received an Equity crowdfunding round in December 2020, with Smart Funding listed as an investor.
- Did Ela Pharma receive any grants?
- Yes, Ela Pharma received a grant of $77,000 USD from the IIA in December 2019.
- What is the current product stage of Ela Pharma's technology?
- Ela Pharma's product is currently in the R&D stage.
- Does Ela Pharma hold any patents?
- Yes, Ela Pharma holds 1 patent.